Literature DB >> 16870269

Suppression of established experimental autoimmune encephalomyelitis and formation of meningeal lymphoid follicles by lymphotoxin beta receptor-Ig fusion protein.

Sandra Columba-Cabezas1, Marilena Griguoli, Barbara Rosicarelli, Roberta Magliozzi, Francesco Ria, Barbara Serafini, Francesca Aloisi.   

Abstract

We have recently shown that de novo formation of lymphoid structures resembling B-cell follicles occurs in the inflamed central nervous system (CNS) meninges in a subset of patients with secondary progressive multiple sclerosis and in SJL mice with relapsing-remitting experimental autoimmune encephalomyelitis (EAE). Because lymphotoxin (LT) alpha(1)beta(2) is essential for lymphoid tissue organization, we used real-time PCR to examine LTbeta and LTbeta receptor (LTbetaR) gene expression in the CNS of SJL mice immunized with PLP 139-151 peptide. Moreover, we used the decoy receptor LTbetaR-immunoglobulin fusion protein to block the interaction of lymphotoxin (LT) alpha(1)beta(2) with the LTbeta receptor (LTbetaR) in mice with established EAE and evaluate the effect of systemic and local treatments with the fusion protein on disease progression, CNS lymphocytic infiltration and formation of meningeal B-cell follicles. The present findings indicate that both LTbeta and LTbetaR are upregulated at EAE onset and during subsequent relapses and that systemic and local blockade of the LT pathway with LTbetaR-Ig results in protracted and transient inhibition of EAE clinical signs, respectively. LTbetaR-Ig treatment also reduces T- and B-cell infiltration and prevents the induction of the chemokines CXCL10 and CXCL13 and the formation of organized ectopic follicles in the EAE-affected CNS. Targeting of molecules involved in lymphoid organogenesis could represent a valid strategy to inhibit CNS inflammation and formation of ectopic follicles, which may play a role in maintaining an abnormal, intrathecal humoral immune response in CNS autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16870269     DOI: 10.1016/j.jneuroim.2006.06.015

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  32 in total

Review 1.  New insights into the development of lymphoid tissues.

Authors:  Serge A van de Pavert; Reina E Mebius
Journal:  Nat Rev Immunol       Date:  2010-08-13       Impact factor: 53.106

Review 2.  The role of B cells in multiple sclerosis: Current and future therapies.

Authors:  Austin Negron; Rachel R Robinson; Olaf Stüve; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2018-10-21       Impact factor: 4.868

3.  Substrain differences reveal novel disease-modifying gene candidates that alter the clinical course of a rodent model of multiple sclerosis.

Authors:  Leslie E Summers deLuca; Natalia B Pikor; Jennifer O'Leary; Georgina Galicia-Rosas; Lesley A Ward; Dustin Defreitas; Trisha M Finlay; Shalina S Ousman; Lucy R Osborne; Jennifer L Gommerman
Journal:  J Immunol       Date:  2010-02-19       Impact factor: 5.422

Review 4.  Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy.

Authors:  Haidong Tang; Mingzhao Zhu; Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2017-04-17       Impact factor: 11.530

Review 5.  Stromal cell regulation of homeostatic and inflammatory lymphoid organogenesis.

Authors:  Matthew J W Kain; Benjamin M J Owens
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

Review 6.  The Lymphotoxin Network: orchestrating a type I interferon response to optimize adaptive immunity.

Authors:  Jennifer L Gommerman; Jeffrey L Browning; Carl F Ware
Journal:  Cytokine Growth Factor Rev       Date:  2014-03-12       Impact factor: 7.638

7.  An interferon-β-resistant and NLRP3 inflammasome-independent subtype of EAE with neuronal damage.

Authors:  Makoto Inoue; Po-Han Chen; Stephen Siecinski; Qi-Jing Li; Chunlei Liu; Lawrence Steinman; Simon G Gregory; Eric Benner; Mari L Shinohara
Journal:  Nat Neurosci       Date:  2016-11-07       Impact factor: 24.884

Review 8.  Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis.

Authors:  Finn Sellebjerg; Diego Cadavid; Deborah Steiner; Luisa Maria Villar; Richard Reynolds; Daniel Mikol
Journal:  Ther Adv Neurol Disord       Date:  2016-01       Impact factor: 6.570

9.  Targeting CXCL13 During Neuroinflammation.

Authors:  Amanda K Huber; David N Irani
Journal:  Adv Neuroimmune Biol       Date:  2015-11-13

10.  B cell repertoire expansion occurs in meningeal ectopic lymphoid tissue.

Authors:  Klaus Lehmann-Horn; Sheng-Zhi Wang; Sharon A Sagan; Scott S Zamvil; H-Christian von Büdingen
Journal:  JCI Insight       Date:  2016-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.